We have located links that may give you full text access.
Antireflux covered metal stent for nonresectable distal malignant biliary obstruction: a multicenter randomized controlled trial.
Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society 2019 Februrary 26
BACKGROUND AND AIM: An antireflux metal stent (ARMS) for nonresectable distal malignant biliary obstruction may prevent recurrent biliary obstruction (RBO) due to the duodenobiliary reflux and prolong time to RBO (TRBO). The superiority of the ARMS over conventional covered self-expandable metal stents (SEMSs) has not been fully examined.
METHODS: We conducted a multicenter randomized controlled trial to examine whether TRBO of an ARMS with a funnel-shaped valve was longer than that of a covered SEMS in SEMS-naïve patients. Secondary outcomes included causes of RBO, adverse events, and patient survival.
RESULTS: We enrolled 104 patients (52 patients per arm) at 11 hospitals in Japan. The TRBO did not differ significantly between the ARMS and covered SEMS groups (median, 251 vs. 351 days, respectively; P = 0.11). RBO due to biliary sludge or food impaction was observed in 13% and 9.8% patients who received an ARMS and covered SEMS, respectively (P = 0.83). The ARMS was associated with a higher rate of stent migration compared with the covered SEMS (31% vs. 12%, P = 0.038). The overall rates of adverse events were 20% and 18% in the ARMS and covered SEMS groups, respectively (P = 0.97). No significant between-group difference in patient survival was observed (P = 0.26).
CONCLUSIONS: The current ARMS was not associated with longer TRBO compared with the covered SEMS. Modifications including addition of an anti-migration system are required to use the current ARMS as first-line palliative treatment of distal malignant biliary obstruction (UMIN-CTR clinical trial registration number: UMIN000014784). This article is protected by copyright. All rights reserved.
METHODS: We conducted a multicenter randomized controlled trial to examine whether TRBO of an ARMS with a funnel-shaped valve was longer than that of a covered SEMS in SEMS-naïve patients. Secondary outcomes included causes of RBO, adverse events, and patient survival.
RESULTS: We enrolled 104 patients (52 patients per arm) at 11 hospitals in Japan. The TRBO did not differ significantly between the ARMS and covered SEMS groups (median, 251 vs. 351 days, respectively; P = 0.11). RBO due to biliary sludge or food impaction was observed in 13% and 9.8% patients who received an ARMS and covered SEMS, respectively (P = 0.83). The ARMS was associated with a higher rate of stent migration compared with the covered SEMS (31% vs. 12%, P = 0.038). The overall rates of adverse events were 20% and 18% in the ARMS and covered SEMS groups, respectively (P = 0.97). No significant between-group difference in patient survival was observed (P = 0.26).
CONCLUSIONS: The current ARMS was not associated with longer TRBO compared with the covered SEMS. Modifications including addition of an anti-migration system are required to use the current ARMS as first-line palliative treatment of distal malignant biliary obstruction (UMIN-CTR clinical trial registration number: UMIN000014784). This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app